Zacks: Analysts Expect Xencor, Inc. (NASDAQ:XNCR) Will Announce Quarterly Sales of $13.05 Million


Share on StockTwits

Equities research analysts forecast that Xencor, Inc. (NASDAQ:XNCR) will announce $13.05 million in sales for the current quarter, according to Zacks. Four analysts have issued estimates for Xencor’s earnings. The lowest sales estimate is $10.72 million and the highest is $15.60 million. Xencor reported sales of $32.39 million in the same quarter last year, which would suggest a negative year over year growth rate of 59.7%. The business is expected to report its next earnings results after the market closes on Wednesday, May 5th.

According to Zacks, analysts expect that Xencor will report full-year sales of $61.12 million for the current financial year, with estimates ranging from $47.14 million to $70.79 million. For the next financial year, analysts forecast that the company will report sales of $78.08 million, with estimates ranging from $23.46 million to $126.90 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Xencor.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, February 23rd. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.30. The business had revenue of $41.85 million during the quarter, compared to the consensus estimate of $21.24 million. Xencor had a negative return on equity of 13.56% and a negative net margin of 113.40%.

A number of equities research analysts recently commented on XNCR shares. Royal Bank of Canada lifted their price target on shares of Xencor from $48.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, February 24th. Barclays lifted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “underweight” rating in a report on Wednesday, February 24th. Zacks Investment Research raised shares of Xencor from a “sell” rating to a “hold” rating in a report on Wednesday, March 24th. SVB Leerink reaffirmed an “outperform” rating on shares of Xencor in a report on Wednesday, February 24th. Finally, Raymond James upgraded shares of Xencor from a “market perform” rating to an “outperform” rating and set a $58.00 price objective for the company in a research note on Tuesday, March 2nd. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $45.80.

In related news, CFO John J. Kuch sold 805 shares of the company’s stock in a transaction on Wednesday, March 3rd. The shares were sold at an average price of $45.09, for a total value of $36,297.45. Following the completion of the transaction, the chief financial officer now directly owns 101,285 shares in the company, valued at $4,566,940.65. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Bassil I. Dahiyat sold 2,850 shares of the company’s stock in a transaction on Wednesday, March 3rd. The stock was sold at an average price of $44.88, for a total transaction of $127,908.00. The disclosure for this sale can be found here. Insiders have sold a total of 19,164 shares of company stock valued at $920,837 over the last 90 days. Company insiders own 3.66% of the company’s stock.

A number of large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC grew its position in Xencor by 10.7% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,100 shares of the biopharmaceutical company’s stock worth $135,000 after acquiring an additional 300 shares in the last quarter. Public Sector Pension Investment Board grew its position in Xencor by 0.3% in the fourth quarter. Public Sector Pension Investment Board now owns 127,092 shares of the biopharmaceutical company’s stock worth $5,545,000 after acquiring an additional 360 shares in the last quarter. Crossmark Global Holdings Inc. grew its position in Xencor by 3.1% in the first quarter. Crossmark Global Holdings Inc. now owns 13,100 shares of the biopharmaceutical company’s stock worth $564,000 after acquiring an additional 390 shares in the last quarter. Comerica Bank grew its position in Xencor by 0.8% in the fourth quarter. Comerica Bank now owns 60,224 shares of the biopharmaceutical company’s stock worth $2,921,000 after acquiring an additional 453 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its position in Xencor by 2.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 23,609 shares of the biopharmaceutical company’s stock worth $1,017,000 after acquiring an additional 669 shares in the last quarter.

XNCR stock traded down $2.39 during mid-day trading on Friday, reaching $41.15. 3,362 shares of the company traded hands, compared to its average volume of 229,891. Xencor has a fifty-two week low of $27.38 and a fifty-two week high of $58.35. The firm’s 50 day moving average price is $43.18 and its 200 day moving average price is $44.40. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -29.39 and a beta of 0.80.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases in the United states and internationally. The company's product candidates include Obexelimab, an immune inhibitor that has completed Phase 2 clinical trial for the treatment of IgG4-related disease and systemic lupus erythematosus, as well as in Phase 1b/2a clinical trial to treat moderate-to-severe rheumatoid arthritis; Plamotamab, a tumor-targeted antibody, which is in Phase 1 clinical trial to treat non-Hodgkin lymphoma; XmAb717, XmAb841, and XmAb104, a bispecific antibody that is in Phase 1 clinical trial to treat patients with selected advanced solid tumors; and Vibecotamab, which is in Phase 1 clinical trial for the treatment of acute myeloid leukemia and other CD123-expressing hematologic malignancies.

Read More: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Xencor (XNCR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.